Physician profile
Rachel M Smith
NPI 1851323919
$8,427.29
in general payments reported to CMS, 2019-2025
29 companies · $2,764 in 2025
The $2,764 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $976 · 2022: $1,172 · 2023: $1,596 · 2024: $1,919 · 2025: $2,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,014 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,013.61 |
| Education | $266.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,030.23 | 2021-2025 | |
| Genzyme Corporation | $757.54 | 2021-2025 | |
| Lilly USA, LLC | $748.31 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $726.76 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $538.21 | 2021-2025 | |
| Janssen Biotech, INC. | $477.40 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $417.17 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $389.25 | 2022-2025 | Sotyktu |
| Medtronic, INC. | $316.76 | 2024-2025 | N/A |
| Galderma Laboratories, L.P. | $279.30 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $226.69 | 2021-2024 | Otezla |
| Leo Pharma INC. | $216.93 | 2021-2025 | Adbry |
| Ucb, INC. | $216.03 | 2021-2025 | Bimzelx |
| Pfizer INC. | $209.89 | 2021-2025 | |
| Incyte Corporation | $177.21 | 2021-2025 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $138.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Organon LLC | $89.57 | 2023-2025 | Vtama, Hadlima |
| Strata Skin Sciences, INC. | $81.59 | 2024 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.62 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.81 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Arcutis Biotherapeutics, INC. | $42.96 | 2023 | |
| Novocure INC. | $31.13 | 2025 | |
| Bausch Health US, LLC | $18.38 | 2024 | Aplenzin |
| Sandoz INC. | $15.77 | 2023 | Hyrimoz |
| Mayne Pharma Commercial LLC | $15.45 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.86 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.65 | 2021 | |
| Biofrontera INC. | $11.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.